Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 230 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Inhaled Steroids Clear all
Recruiting Early Phase 1 Interventional

Timely Administration of IV Magnesium Sulfate in Patients With a Moderate Asthma Exacerbation

NCT06137040
View directory record Official record
Conditions
Asthma in Children, Asthma Attack
Interventions
Magnesium Sulfate within the first hour, No Magnesium sulfate within the first hour
Drug · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
5 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Altitude Sickness Prevention and Efficacy of Comparative Treatments

NCT02604173
View directory record Official record
Conditions
Acute Mountain Sickness
Interventions
Budesonide, Acetazolamide, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Bishop, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep

NCT00731770
View directory record Official record
Conditions
COPD
Interventions
Advair 250, Placebo- matched, Placebo, Advair 250 - matched
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
45 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Not applicable Interventional

Clinical Endpoint Bioequivalence Study of Fluticasone Propionate & Salmeterol Xinafoate (100μg/50μg)

NCT03535870
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone propionate/salmeterol, Advair Diskus, 100 Mcg-50 Mcg Inhalation Powder, Placebo
Drug
Lead sponsor
West-Ward Pharmaceutical
Industry
Eligibility
12 Years to 65 Years
Enrollment
1,556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Nov 28, 2019 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Not applicable Interventional Results available

Effect of Nitrous Oxide in Treating Neuropathic Pain: A Study in Chronic Low Back Pain Patients

NCT01172600
View directory record Official record
Conditions
Low Back Pain, Radiating Pain
Interventions
Entonox, Oxygen
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2016 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease

NCT02061202
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Mometasone Furoate, Placebo
Drug
Lead sponsor
Jeffrey Glassberg
Other
Eligibility
15 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2019 · Synced Sep 2, 2026, 7:14 AM EDT
Recruiting Not applicable Interventional

Platform of Randomized Adaptive Clinical Trials in Critical Illness

NCT05440851
View directory record Official record
Conditions
Respiratory Insufficiency, Extracorporeal Membrane Oxygenation Complication, Mechanical Ventilation Pressure High
Interventions
Ultra-Protective Ventilation Facilitated by Extracorporeal Support, Lung-Protective Ventilation (LPV), Driving Pressure-Limited Ventilation (DPL), Lung- and Diaphragm-Protective Ventilation and Sedation (LDPVS), Early Cohort corticosteroid dose, Extended Cohort corticosteroid dose, Usual care without routine corticosteroids, Usual care without extending corticosteroids, Usual care with fludrocortisone, Usual care without fludrocortisone, Drug 4 mL:, Drug 40 mg:, PEEP-20, PEEP-AOP, PEEP-10, VV ECMO-facilitated strategy of earlier awakening, extubation and rehabilitation, Electrical impedance tomography (EIT), no treatment / intervention arm is involved., Usual care, Early Routine IMT
Other · Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
26
States / cities
Tucson, Arizona • Los Angeles, California • San Diego, California + 19 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of SAR440340 and as Combination Therapy With Dupilumab in Moderate-to-Severe Asthma Participants

NCT03387852
View directory record Official record
Conditions
Asthma
Interventions
SAR440340, Dupilumab, Fluticasone or Fluticasone/salmeterol combination, Placebo for SAR440340, Placebo for dupilumab
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
18
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2022 · Synced Sep 2, 2026, 7:14 AM EDT
Not listed Not applicable Interventional

Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain

NCT00087815
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Radiation Toxicity
Interventions
dexamethasone, hyperbaric oxygen, cognitive assessment, magnetic resonance imaging, positron emission tomography, quality-of-life assessment
Drug · Procedure
Lead sponsor
Barrett Cancer Center
Other
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 17, 2013 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

The Effect on Depressive Symptoms in ECF Residents With COPD

NCT00974246
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Depression
Interventions
Advair diskus
Drug
Lead sponsor
Valley Medical Research
Other
Eligibility
18 Years to 94 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Brooksville, Florida • Centerville, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 27, 2016 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Step-up Yellow Zone Inhaled Corticosteroids to Prevent Exacerbations

NCT02066129
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone 44 mcg, Fluticasone 220 mcg
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
5 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
18
States / cities
Tucson, Arizona • Oakland, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

MethaCholine Bronchoprovocation Study (MeCIS)

NCT00705341
View directory record Official record
Conditions
Asthma
Interventions
fluticasone
Drug
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
12 Years to 69 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
13
States / cities
San Diego, California • Jacksonville, Florida • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT03478683
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler
Drug · Device
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
729 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
40
States / cities
Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2020 · Synced Sep 2, 2026, 7:14 AM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Targeted Therapy of Bronchiolitis Obliterans Syndrome

NCT01307462
View directory record Official record
Conditions
Bronchiolitis Obliterans
Interventions
fluticasone propionate, montelukast sodium, azithromycin
Drug
Lead sponsor
Stephanie Lee
Other
Eligibility
6 Years to 99 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Scottsdale, Arizona • Stanford, California • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Addition of Fluticanse Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide (62.5 or 125mcg) Once-daily Over 12 Weeks

NCT01772134
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
617 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
13
States / cities
Jasper, Alabama • Clearwater, Florida • Ormond Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2018 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) on Exercise-induced Bronchoconstriction in Adults and Adolescents With Asthma

NCT04234464
View directory record Official record
Conditions
Exercise Induced Bronchospasm
Interventions
Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Placebo metered-dose inhaler
Combination Product
Lead sponsor
Bond Avillion 2 Development LP
Industry
Eligibility
12 Years to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
6
States / cities
Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2022 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Steroid-Free Versus Steroid-Based Immunosuppression in Pediatric Renal (Kidney) Transplantation

NCT00141037
View directory record Official record
Conditions
Kidney Diseases, Kidney Transplantation, Kidney Transplant, Renal Transplantation, Renal Transplant
Interventions
Daclizumab, Mycophenolate mofetil (MMF), Prednisone, Tacrolimus, Ganciclovir, Valganciclovir, Trimethoprim and sulfamethoxazole
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 21 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2016 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults

NCT06723756
View directory record Official record
Conditions
Healthy Participants
Interventions
Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT00669617
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol
Drug
Lead sponsor
Novartis
Industry
Eligibility
40 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
5
States / cities
Tamarac, Florida • Lafayette, Louisiana • Saint Charles, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2011 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

ACTIV-6: COVID-19 Study of Repurposed Medications - Arm C (Fluticasone)

NCT05736874
View directory record Official record
Conditions
Covid19
Interventions
Fluticasone, Placebo
Drug · Other
Lead sponsor
Susanna Naggie, MD
Other
Eligibility
30 Years and older
Enrollment
1,407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
87
States / cities
Gilbert, Arizona • Mesa, Arizona • Peoria, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced Sep 2, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years Old

NCT01462344
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR 100/50mcg, ADVAIR 250/50mcg, FLOVENT 100mcg, FLOVENT 250mcg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
6,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
267
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 208 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Sep 2, 2026, 7:14 AM EDT
Recruiting Phase 3 Interventional

A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

NCT06664619
View directory record Official record
Conditions
Asthma
Interventions
Fp/ABS, FP, ABS, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
12 Years and older
Enrollment
724 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
91
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 73 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 2, 2026, 7:14 AM EDT